PMID- 19468200
OWN - NLM
STAT- MEDLINE
DCOM- 20091027
LR  - 20151119
IS  - 1421-9832 (Electronic)
IS  - 1018-8665 (Linking)
VI  - 219
IP  - 1
DP  - 2009
TI  - Refractory chronic cutaneous sarcoidosis responsive to dose escalation of 
      TNF-alpha antagonists.
PG  - 59-62
LID - 10.1159/000221005 [doi]
AB  - Cutaneous sarcoidosis may be a chronic disease with important morbidity requiring 
      aggressive therapy. The efficacy of different anti-tumor necrosis factor 
      alpha(anti-TNF-alpha) treatments in refractory cutaneous and systemic sarcoidosis 
      has been reported previously. We report the first patient with chronic cutaneous 
      sarcoidosis who responded to dose escalation of anti-TNF-alpha agents that have 
      been ineffective at the standard dosage, illustrating that the optimal dosing 
      regimen has still to be defined for this indication before considering 
      difficult-to-treat patients as nonresponders. Our case report also illustrates 
      that the fusion protein etanercept, even used at a high dosage, may be less 
      effective for the treatment of cutaneous sarcoidosis than the monoclonal 
      antibodies infliximab and adalimumab.
CI  - 2009 S. Karger AG, Basel.
FAU - Thielen, A-M
AU  - Thielen AM
AD  - Dermatology Department, Hopitaux Universitaires de Geneve, Geneva, Switzerland. 
      anne-marie.thielen@hcuge.ch
FAU - Barde, C
AU  - Barde C
FAU - Saurat, J-H
AU  - Saurat JH
FAU - Laffitte, E
AU  - Laffitte E
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20090525
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Infliximab
MH  - Sarcoidosis/*drug therapy
MH  - Skin Diseases/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2009/05/27 09:00
MHDA- 2009/10/29 06:00
CRDT- 2009/05/27 09:00
PHST- 2009/03/30 00:00 [received]
PHST- 2009/04/17 00:00 [accepted]
PHST- 2009/05/27 09:00 [entrez]
PHST- 2009/05/27 09:00 [pubmed]
PHST- 2009/10/29 06:00 [medline]
AID - 000221005 [pii]
AID - 10.1159/000221005 [doi]
PST - ppublish
SO  - Dermatology. 2009;219(1):59-62. doi: 10.1159/000221005. Epub 2009 May 25.